Confronting complex medical challenges
Communiqué takes a deep dive into how Mayo Clinic Laboratories advances patient care, research, and education through laboratory medicine. Our experts are solving the most serious and complex medical challenges for patients worldwide.
Mayo Clinic’s Advanced Diagnostics Laboratory (ADL) is a visionary space designed to foster innovation. The ADL has a direct impact on patient lives, bringing promising tests and services to patients at Mayo and around the world.
For patients with chronic lymphocytic leukemia (CLL) — the most common leukemia in adults — advanced testing can not only provide valuable information about their disease state, but peace of mind in the face of a progressive, incurable illness. Oftentimes, however, complex molecular and genetic tests to identify biomarker cues about disease trajectory and treatment intolerance are not performed, putting patients at risk for unmet expectations and unsatisfactory outcomes.
A collaborative study between Mayo Clinic and the University of Illinois debunked the previous consensus about how kidney stones grow.
Part II of this series shows how a breakthrough discovery about how kidney stones form may open the way for new, unorthodox treatments. The discovery was made possible by joining University of Illinois’ geology and biology forces with Mayo Clinic’s urology and nephrology expertise.
Dr. Dollahite received world-class cancer treatment from a web of health care organizations, including Mayo Clinic in Rochester, Minnesota. Yet she never left New York; most of her treatment occurred in Ithaca. What made that possible was Cayuga Medical Center’s collaborative relationship with Mayo Clinic. Genetic testing at Mayo Clinic Laboratories provided important information about Dr. Dollahite’s cancer.
For community health care providers, owning a laboratory has been likened to shoveling money down a giant drain. Cayuga Medical Center is challenging that narrative. Instead of selling, Cayuga is investing in its lab — which it considers a value center as well as a key part of patient service.
Mayo Clinic's use of enhanced radio-frequency identification technology to track specimens from the clinical setting to the lab reduces the risk of errors and protects valuable — sometime irreplaceable — patient samples.
With the rise of next generation sequencing (NGS) technology, multigene panel testing is expanding so rapidly that clinical practice is racing to keep pace. And questions within genetic tests have expanded along with it, making definitive answers more challenging to come by. Experts in the Genomics Laboratory in Mayo Clinic's Department of Laboratory Medicine and Pathology work to explain this often misunderstood technology.
A massive effort that involved numerous departments and experts, culminated in Mayo Clinic designing, testing and mass-manufacturing a 3D-printed mid-turbinate swab for COVID-19 testing.
Flu season is just now unfolding. But this time, it’s piggy-backed with a pandemic, which threatens to spike with the colder weather as people huddle indoors. Adding to this conundrum is the unsettling fact that, for both COVID-19 and the flu, the symptoms overlap.
One of the biggest misunderstandings about genetic testing is a perception that once a variant is identified and analyzed thoroughly, using all the best tools available, it can be associated with a specific disease or condition. But many mutations are deemed “variants of unknown significance,” meaning there is no reported (or insufficient) evidence as to whether or not they cause disease.
In the last decade or so, genetic testing has evolved from single-gene Sanger based assays to much more complex next-generation sequencing (NGS) based assays. This incredible technology has facilitated the rapid and high-throughput evaluation of many genes (hundreds of thousands of DNA strands) all at once.